Research programme: autoimmune disorders therapeutics - Inventiva Pharma/ Abbvie

Drug Profile

Research programme: autoimmune disorders therapeutics - Inventiva Pharma/ Abbvie

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inventiva Pharma
  • Developer AbbVie; Inventiva Pharma
  • Class Small molecules
  • Mechanism of Action Immunosuppressants; Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Psoriasis
  • Research Autoimmune disorders

Most Recent Events

  • 13 Sep 2017 Inventiva extended its agreement with Abbvie to develop orally available RORγ inverse agonists for autoimmune diseases
  • 09 May 2017 Preclinical trials in Psoriasis in USA (PO) before May 2017 (NCT03145948)
  • 20 Nov 2015 Early research in Autoimmune disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top